Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

Genentech is planning cuts on the Peninsula.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall s.

Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus.

Genentech’s overarching campaign is part of the company’s embrace of diversity, equity and inclusion efforts, including diversifying its clinical trials and its supplier base, Dunn said.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. For decades, the biotech company Genentech has carved out a reputation in the ...